<DOC>
	<DOC>NCT01348425</DOC>
	<brief_summary>This randomized, post-market clinical study is intended to evaluate the delivery and deployment of longer Zilver PTX stents (≥ 100 mm) compared to shorter Zilver PTX stents (≤80 mm) for treatment of lesions of the above-the-knee femoropopliteal artery.</brief_summary>
	<brief_title>Zilver PTX Drug-Eluting Peripheral Stent Study</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>One de novo or restenosed artherosclerotic lesion with &gt; 50% diameter stenosis Reference vessel diameter of 4 9 mm Rutherford category ≥ 2 Resting ankle brachial index &lt; 0.9 Prior stent in the study vessel Significant stenosis (&gt; 50%) or occlusion of inflow tract not successfully treated before the study procedure Lacks at least one patent runoff vessel Lesions requiring atherectomy, cutting balloons, cryoplasty balloons, or any other advanced device to facilitate stent delivery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>PAD</keyword>
</DOC>